Previous close | 0.9400 |
Open | 0.9100 |
Bid | 0.9500 x 14831600 |
Ask | 0.9000 x 5161300 |
Day's range | 0.9000 - 0.9400 |
52-week range | 0.9000 - 5.0000 |
Volume | |
Avg. volume | 4,311 |
Market cap | 10.666M |
Beta (5Y monthly) | 1.33 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.0800 |
Earnings date | 29 Aug 2023 - 04 Sept 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), a global leader in the research, development and commercialization of clinically validated cannabinoid medicines, is pleased to announce the launch of ZYRAYDI™, its patented, licensable technology for the future of the medical cannabis industry.
Zelira Therapeutics Ltd (ASX: ZLD, OTC-QB: ZLDAF), a global leader in the research, development and commercialization of clinically validated cannabinoid medicines, is pleased to announce that its groundbreaking insomnia medication Zenivol™ has achieved formal approval from German regulatory authority BfArM to launch in the German medical cannabis market.
We can readily understand why investors are attracted to unprofitable companies. For example, although...